US2010081810A1PendingUtilityA1

C-Pyrazole A2A Receptor Agonists

68
Assignee: ZABLOCKI JEFF APriority: Jun 22, 1999Filed: Jun 25, 2009Published: Apr 1, 2010
Est. expiryJun 22, 2019(expired)· nominal 20-yr term from priority
A61P 9/00A61P 7/02A61P 7/00A61P 9/08A61P 9/10A61P 29/00C07H 19/16A61K 31/7076
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Claims

exact text as granted — not AI-modified
1 . A compound of matter having the formula: 
       
         
           
           
               
               
           
         
       
       wherein R 1  is —CH 2 OH, —C(═O)NR 5 R 6 ;
 R 2  is selected from the group consisting of hydrogen, C 1-15  alkyl, C 2-15  alkenyl, C 2-15  alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO 2 , heterocyclyl, aryl, heteroaryl, CF 3 , CN, OR 20 , SR 20 , N(R 20 )2, S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , SO 2 NR 20 COR 22 , SO 2 NR 20 C0 2 R 22 , SO 2 NR 20 CON(R 20 ) 2 , N(R 20 ) 2 , NR 20 COR 22 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , NR 20 C(NR 20 )NHR 23 , COR 20 , CO2R 20 , CON(R 20 ) 2 , and OCON(R 20 ) 2  and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO 2 , alkyl, CF 3 , amino, mono- or di-alkylamino, alkyl or aryl or heteroaryl amide, NCOR 22 , NR 20 SO 2 R 22 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 CON(R 20 ), OC(O)N(R 20 ) 2 ; SR 20 , S(O)R 22 , SO2R 22 , SO 2 N(R 20 ) 2 , CN, and OR 20 ; 
 R 3 , R 4  are each individually selected from the group consisting of hydrogen, C 1-15 , alkyl, C 2-15 , alkenyl, C 2-15 , alkynyl, heterocyclyl, aryl, and heteroaryl, halo, NO 2 , CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R20) 2 , SO 2 NR 20 COR 22 , SO 2 NR 20 R 22 , SO 2 NR 20 CON(R 20 ) 2 , N(R 20 ) 2  NR 20 COR 22 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , NR 20 C(NR 20 )NHR 23 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , CONR 20 SO 2 R 22 , NR 20 SO 2 R 22 , SO 2 NR 20 CO 2 R 22 , OCONR 20 SO 2 R 22 , OC(O)R 20 , C(O)OCH 2 OC(O)R 20 , and OCON(R 20 ) 2 , wherein the alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from the group consisting of halo, NO 2 , heterocyclyl, aryl, heteroaryl, CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , SO 2 NR 20 COR 22 , SO 2 NR 20 CO 2 R 22 , SO 2 NR 20 CON(R 20 ) 2 , N(R 20 ) 2  NR 20 COR 22 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , SO 2 NR 20 CO 2 R 22 , OCONR 20 SO 2 R 22 , OC(O)R 20 , C(O)OCH 2 OC(O)R 20 , and OCON(R 20 ) 2 , and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO 2 , alkyl, CF 3 , amino, mono- or di-alkylamino, alkyl or aryl or heteroaryl amide, NCOR 22 , NR 20 SO 2 R 22 , COR 20 , CO2R 20 , CON(R 20 ) 2 , NR 20 CON(R 20 ) 2 , OC(O)R 20 , OC(O)N(R 20 ) 2 , SR 20 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , CN, AND OR 20 ; 
 R 5  and R 6  are each individually selected from H, C 1-15 , alkyl with from 1 to 2 substituents independently selected from the group consisting of halo, NO 2 , heterocyclyl, aryl, heteroaryl, CF 3 , CN, OR 20 , SR 20 , N(R 20 ) 2 , S(O)R 22 , SO 2 R 22 , SO 2 N(R 20 )2, SO 2 NR 20 COR 22 , SO 2 NR 20 CO 2 R 22 , SO 2 NR 20 CON(R 20 ) 2 , N(R 20 ) 2 , NR 20 COR 22 , NR 20 CO 2 R 22 , NR 20 CON(R 20 ) 2 , NR 20 C(NR 20 )NHR 23 , COR 2 O, CO 2 R 20 , CON(R 20 ) 2 , CONR 20 SO 2 R 22 , NR 20 SO 2 R 22 , SO 2 NR 20 CO 2 R 22 , OCONR 20 SO 2 R 22 , OC(O)R 20 , C(O)OCH 2 OC(O)R 20 , and OCON(R 20 ) 2 , and wherein each optional heteroaryl, aryl, and heterocyclyl substituent is optionally substituted with halo, NO 2 , alkyl, CF 3 , amino, mono- or di-alkylamino, alkyl or aryl or heteroaryl amide, NCOR 22 , NR 20 SO2R 22 , COR 20 , CO 2 R 20 , CON(R 20 ) 2 , NR 20 CON(R 20 ) 2 , OC(O)R 20 , OC( )N(R 20 ) 2 , SR 20 , S( )R 22 , SO 2 R 22 , SO 2 N(R 20 ) 2 , CN, AND OR 20 ; 
 R 20  is selected from the group consisting of H, C 1-15 , alkyl, C 2-15  alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino; alkyl or aryl or heteroaryl amide, CN, O—C 1-6 , alkyl, CF 3 , aryl, and heteroaryl; and 
 R 22  is a member selected from the group consisting of C 1-15 , alkyl, C 2-15 , alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heterocyclyl, aryl, and heteroaryl substituents are optionally substituted with from 1 to 3 substituents independently selected from halo, alkyl, mono- or dialkylamino, alkyl or aryl or heteroaryl amide, CN, O—C 1-16 , alkyl, CF 3 , and heteroaryl wherein, when R 1  is CH 2 OH, and R 3  is H and R 4  is H, and the pyrazole ring is attached through C 4 , then R, is not H. 
 
     
     
         2 .- 34 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.